Dupilumab in Patients with Atopic Dermatitis: A Multicentric, Long-Term, Real-World Portuguese Study

  • Published on 09/02/2024
  •  Reading time: 5 min.

Tiago Torres   1 ,2 , Maria João Cruz 3 , Maria João Paiva Lopes 12  

1 Department of Dermatology, CAC ICBAS-CHP - Centro Académico Clínico ICBAS - CHP, Porto, Portugal
2 UMIB - Unit for Multidisciplinary Research in Biomedicine, Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal
3 Dermatology Department, ULS São João, Porto, Portugal
12 CRI de Dermatovenereologia, Hospital de Santo António dos Capuchos, ULS São José, Lisbon, Portugal

Abstract

Introduction Several clinical trials have established the efficacy and safety of dupilumab for treating atopic dermatitis (AD). However, literature remains scarce in reporting the long-term effectiveness, safety, and drug survival of dupilumab in real-world settings. This study aimed to describe the latter outcomes of dupilumab in patients with AD.
Methods This Portuguese, multicentric, observational, retrospective study included consecutive adult patients...

ContentGeneMD

To continue reading this article in Full-Text...

* Access is totally free, without commitment or condition. Service exclusively reserved for healthcare professionals.

Peer-Reviewed Journals A-Z

Search | Advanced search

Get the latest news in Dermatology

Receive our newsletter to stay up to date with the latest news in Dermatology